SCHEMBL24399737

SCHEMBL24399737

Cc1ccc2c(Nc3ccc(C#N)cc3F)nccc2c1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.40
FGFR1 P11362 2/20 0.40
FLT1 P17948 2/20 0.40
FLT4 P35916 2/20 0.40
FGFR2 P21802 1/20 0.40
FGFR4 P22455 1/20 0.40
FGFR3 P22607 1/20 0.40
BRAF P15056 2/20 0.39
LCK P06239 1/20 0.39
TEK Q02763 1/20 0.39
EGFR P00533 1/20 0.37
GPR119 Q8TDV5 5/20 0.37
KCNH2 Q12809 1/20 0.37
PDGFRB P09619 1/20 0.36
CSNK1D P48730 1/20 0.35
CSNK1G2 P78368 1/20 0.35
MAP2K1 Q02750 4/20 0.35
GAK O14976 1/20 0.34
RIPK2 O43353 1/20 0.34
COQ8A Q8NI60 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30402491 1.00 KDR (0.40) KDRFGFR1FLT1FLT4FGFR2
SCHEMBL30400458 0.91 BACE2 (0.39) KDRFGFR1FLT1FLT4FGFR2
SCHEMBL25374814 0.91 BACE2 (0.39) KDRFGFR1FLT1FLT4FGFR2
SCHEMBL24399688 0.84 FGFR1 (0.44) KDRFGFR1FLT1BRAFRAF1
SCHEMBL26210494 0.84 HDAC3 (0.44) KDRFGFR1FLT1FLT4BRAF
SCHEMBL26207944 0.82 KDR (0.46) KDRFGFR1FLT1FLT4FGFR2
SCHEMBL25374853 0.82 GPR119 (0.43) KDRFGFR1FLT1FLT4FGFR2
SCHEMBL30401854 0.82 GPR119 (0.43) KDRFGFR1FLT1FLT4FGFR2
SCHEMBL24399714 0.82 EGFR (0.36) KDRFGFR1FLT1BRAFLCK
SCHEMBL29638638 0.82 EGFR (0.36) KDRFGFR1FLT1BRAFLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
CN-116096718-A Aryl amide compound, pharmaceutical composition containing same, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-05-09 CN disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 WO disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM KDR 2780/4885FGFR1 256/4885FLT1 1194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.